全文获取类型
收费全文 | 1149篇 |
免费 | 50篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 4篇 |
妇产科学 | 9篇 |
基础医学 | 191篇 |
口腔科学 | 8篇 |
临床医学 | 178篇 |
内科学 | 227篇 |
皮肤病学 | 17篇 |
神经病学 | 26篇 |
特种医学 | 13篇 |
外科学 | 262篇 |
综合类 | 11篇 |
一般理论 | 1篇 |
预防医学 | 80篇 |
眼科学 | 20篇 |
药学 | 66篇 |
中国医学 | 5篇 |
肿瘤学 | 70篇 |
出版年
2023年 | 4篇 |
2022年 | 8篇 |
2021年 | 17篇 |
2020年 | 20篇 |
2019年 | 16篇 |
2018年 | 19篇 |
2017年 | 15篇 |
2016年 | 11篇 |
2015年 | 27篇 |
2014年 | 27篇 |
2013年 | 38篇 |
2012年 | 66篇 |
2011年 | 76篇 |
2010年 | 43篇 |
2009年 | 38篇 |
2008年 | 87篇 |
2007年 | 72篇 |
2006年 | 60篇 |
2005年 | 81篇 |
2004年 | 71篇 |
2003年 | 64篇 |
2002年 | 38篇 |
2001年 | 31篇 |
2000年 | 31篇 |
1999年 | 20篇 |
1998年 | 11篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 6篇 |
1994年 | 5篇 |
1992年 | 11篇 |
1991年 | 12篇 |
1990年 | 16篇 |
1989年 | 16篇 |
1988年 | 7篇 |
1987年 | 11篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1982年 | 6篇 |
1981年 | 7篇 |
1980年 | 9篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1975年 | 9篇 |
1974年 | 5篇 |
1972年 | 5篇 |
1971年 | 3篇 |
1969年 | 3篇 |
1968年 | 5篇 |
排序方式: 共有1203条查询结果,搜索用时 15 毫秒
1.
2.
In rare cases the usage of the internal thoracic vessels as recipient vessels in reconstructive surgery of the head and neck region with free tissue transfer is a challenging but valid alternative if local recipient vessels are unusable. 相似文献
3.
Lutz Fritsche Klemens Budde Hans-Hellmut Neumayer 《Nephrology, dialysis, transplantation》2003,18(3):621-2; author reply 622
Sir, The paper by Zeier and Ritz in the April 2002 issue of NDT [1]is a good reminder of the importance of evaluation and selectionof kidney transplant candidates. Also, this paper clearly demonstratesthe persisting lack of clinical evidence in this field, whichhas considerable impact on large numbers of end-stage renaldisease patients. We have previously demonstrated the unexplained variations inthe evaluation 相似文献
4.
B.E. Jones C.B. Boylan M. Fritsche M. Juhasz C. Jackson S.J. Wiegand C. Hyman R.M. Lindsay C.A. Altar 《Brain research》1996,709(2):275
Rat models of Parkinson's disease typically employ a rapid nigral injection of 6-hydroxydopamine (6-OHDA) to produce a near-complete loss of nigrostriatal dopamine neurons, and thus model end stage disease. The present report describes the use of a continuous, low dose infusion of 6-OHDA into the striatum which produces a terminal axotomy of nigrostriatal dopamine neurons and protracted behavioral response. A solution of 6-OHDA in 0.4% ascorbate, delivered at 37°C from osmotic minipumps, was stable for 8 days as determined by its retained toxicity to a dopaminergic neuroblastoma cell line. The continuous infusion of 0.2 μg 6-OHDA per h did not affect the striatal uptake of [3H]GABA, [3H]choline, or [3H]glutamate but reduced [3H]dopamine uptake by 55% within 1.5 days after the start of the infusion. The striatal infusion of 6-OHDA produced a dose-dependent reduction of striatal dopamine and DOPAC levels but did not alter HVA, 5-HT, or 5-HIAA. An increase in amphetamine-induced ipsiversive rotations occurred within 1.5 days after the acute striatal injection of 20 μg or 30 μg of 6-OHDA but required 4 days to develop with the continuous 6-OHDA infusion. The topography of the lesion mapped by [3H]mazindol binding showed that, begining by 1.5 days, a diffuse depletion of terminals encompassed much of the striatum in the 30 μg acute injection group, whereas in the continuously infused rats, the lesion was apparent only by 4 days and was restricted to a smaller and more completely lesioned area. Unlike acutely lesioned animals, continuously infused rats revealed no obvious loss of dopamine neurons in the pars compacta by 5 weeks after 6-OHDA. The continuous striatal infusion of 6-OHDA can produce a topographically limited terminal axotomy of dopamine neurons and a protracted behavioral impairment. 相似文献
5.
Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. 总被引:3,自引:0,他引:3
K Koppenhagen J Adolf M Matthes E Tr?ster J D Roder S Hass H M Fritsche H Wolf 《Thrombosis and haemostasis》1992,67(6):627-630
In a prospective, double-blind, randomized multicenter trial the efficacy and safety of low molecular weight heparin and unfractionated heparin were compared for the prevention of postoperative deep vein thrombosis in patients undergoing abdominal surgery. Six hundred and seventy-three patients were randomly allocated to the two prophylaxis groups; 20 of these, however, did not undergo surgery and did not receive any prophylaxis. Of the remaining 653 patients 323 received one subcutaneous injection of 3,000 anti-Xa units of low molecular weight heparin and 330 received subcutaneously 5,000 U heparin three times a day. Treatment was initiated 2 h preoperatively and continued for 7 to 10 days. The occurrence of DVT was determined by the 125I-labelled fibrinogen uptake test and phlebography. Venous thrombosis was diagnosed in 24 of 323 patients (7.4%) treated with low molecular weight heparin and in 26 of 330 patients (7.9%) treated with low-dose heparin. DVT of proximal veins was detected in four patients of the low molecular weight heparin group and in three patients of the low-dose heparin group. During the observation period three pulmonary emboli - one fatal and two non-fatal - occurred in patients receiving prophylaxis with low-dose heparin. No pulmonary embolism was found in patients treated with low molecular weight heparin. Both prophylactic schemes were well tolerated. Intra- and postoperative blood loss, incidence of wound hematoma, frequency and volume of intra- and postoperative blood transfusion were similar in both groups with a slight advantage for the low molecular weight heparin group.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
6.
Lutz Fritsche Gunilla Einecke Franca Fleiner Duska Dragun Hans-Hellmut Neumayer Klemens Budde 《American journal of transplantation》2004,4(5):738-743
The reporting quality of publications of clinical trials can affect the quality of clinical decision-making. We systematically assessed the quality of publications of large multicenter trials evaluating immunosuppressive regimens in de novo kidney transplantation. Study quality, reporting quality and accessibility of the results of 63 publications were assessed independently by three blinded investigators using an instrument combining the Jadad scale with a list of reporting quality items. Study quality was rated with an average of only 2.3 (range 1-5) on the Jadad scale. Unblinded studies were reported in 68.3% of publications and follow-up longer than 12 months was reported for only 13 out of 50 studies. The reviewed publications fulfilled an average of 69.1% of the reporting quality criteria. Fifty-four percent of publications did not report both treated and biopsy-proven rejections. Whether reported graft survival was censored for death could not be determined for 27% of publications. Only a few publications gave confidence intervals (CIs) or stated whether additional analyses were pre-specified. Even the largest trials of immunosuppression in kidney transplantation show considerable quality deficits in their design and publication. Additional efforts are required of investigators, editors and sponsors to achieve maximum study and reporting quality. 相似文献
7.
8.
Robert C Bast Hans Lilja Nicole Urban David L Rimm Herbert Fritsche Joe Gray Robert Veltri George Klee Andrew Allen Nam Kim Steven Gutman Mark A Rubin Andrew Hruszkewycz 《Clinical cancer research》2005,11(17):6103-6108
A group of investigators met at a Specialized Programs of Research Excellence Workshop to discuss key issues in the translation of biomarker discovery to the development of useful laboratory tests for cancer care. Development and approval of several new markers and technologies have provided informative examples that include more specific markers for prostate cancer, more sensitive tests for ovarian cancer, more objective analysis of tissue architecture and an earlier indication of response to treatment in breast cancer. Although there is no clear paradigm for biomarker development, several principles are clear. Marker development should be driven by clinical needs, including early cancer detection, accurate pretreatment staging, and prediction of response to treatment, as well as monitoring disease progression and response to therapy. Development of a national repository that uses carefully preserved, well-annotated tissue specimens will facilitate new marker development. Reference standards will be an essential component of this process. Both hospital-based and commercial laboratories can play a role in developing biomarkers from discovery to test validation. Partnering of academe and industry should occur throughout the process of biomarker development. The National Cancer Institute is in a unique position to bring together academe, industry, and the Food and Drug Administration to (a) define clinical needs for biomarkers by tumor type, (b) establish analytic and clinical paradigms for biomarker development, (c) discuss ways in which markers from different companies might be evaluated in combination, (d) establish computational methods to combine data from multiple biomarkers, (e) share information regarding promising markers developed in National Cancer Institute-supported programs, and (f) exchange data regarding new platforms and techniques that can accelerate marker development. 相似文献
9.
Squamous cell carcinoma antigen (TA-4) in penile carcinoma 总被引:1,自引:0,他引:1
TA-4 antigen, originally isolated from women with squamous cell carcinoma of the cervix, is elevated in the sera of patients with squamous cell carcinomas of several sites, including esophagus, lungs, and head and neck. In this study, we compared the serum levels of TA-4 in normal volunteers, patients with resected penile squamous cell carcinoma, and patients with metastatic penile squamous cell carcinoma. TA-4 values were elevated in 5 of 11 patients (45%) who had metastatic disease. In 2, TA-4 was normal the first time metastasis was clinically detected but rose as the disease progressed. Moreover, in 3 patients in whom serial determinations were made, serum TA-4 values correlated well with disease progression and response to treatment. We conclude that TA-4 values are elevated in some patients with metastatic squamous cell carcinoma of the penis and may become a useful marker for monitoring response to therapy. 相似文献
10.
Rivera A Fisher SA Fritsche LG Keilhauer CN Lichtner P Meitinger T Weber BH 《Human molecular genetics》2005,14(21):3227-3236
Age-related macular degeneration (AMD) is a multifactorial disease and a prevalent cause of visual impairment in developed countries. Risk factors include environmental components and genetic determinants. The complement factor H (CFH) has been the first major susceptibility gene for AMD identified within 1q32. Here, we focused on a second region of interest in 10q26 where a recent meta-analysis revealed strongest evidence for linkage to AMD at a genome-wide significance level. Within an interval of 22 Mb, we have analyzed 93 single nucleotide polymorphisms for allelic association with AMD in two independent case-control cohorts of German origin (AMD(combined) n=1166; controls(combined) n=945). Significant association was found across a 60 kb region of high linkage disequilibrium harboring two genes PLEKHA1 and hypothetical LOC387715. The strongest association (P=10(-34)) centered over a frequent coding polymorphism, Ala69Ser, at LOC387715, strongly implicating this gene in the pathogenesis of AMD. Besides abundant expression in placenta, we demonstrate weak expression of LOC387715 in the human retina. At present, however, there is no functional information on this gene, which appears to have evolved recently within the primate lineage. The joint contribution of the common risk allele at LOC387715, Ala69Ser, and at CFH, Tyr402His, was assessed in our case-control population, which suggests an additive model indicating an independent contribution of the two gene loci to disease risk. Our data show a disease odds ratio of 57.6 (95% CI: 37.2, 89.0) conferred by homozygosity for risk alleles at both CFH and LOC387715 when compared with the baseline non-risk genotype. 相似文献